Faculty Collaboration Database

Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer 2008 Mar;50(3):667-70

Date

02/24/2007

Pubmed ID

17318876

DOI

10.1002/pbc.21171

Scopus ID

2-s2.0-38549129707   21 Citations

Abstract

We report a novel regimen for refractory post-transplant T-cell lymphoma (PTL). Our patient presented with non-Epstein-Barr virus (EBV) related, T-cell post-transplant lymphoproliferative disease (PTLD) 3.5 years after liver transplantation. Initially diagnosed as polyclonal PTLD, the disease progressed to a monoclonal, T-cell PTL that was refractory to several chemotherapy regimens but responded to a regimen consisting of fludarabine, cyclophosphamide, cytarabine, and alemtuzumab. Consolidation therapy included high-dose chemotherapy, autologous hematopoietic stem cell rescue, and radiation therapy. She remains in remission 2.5 years later. T-cell PTL is a rare disease with a poor prognosis; this regimen provides a novel, potentially curative approach for its treatment.

Author List

Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ

Author

Cindy L. Schwartz MD, MPH Chief, Professor in the Pediatrics department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Alemtuzumab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antineoplastic Combined Chemotherapy Protocols
Biliary Atresia
Carboplatin
Carmustine
Cyclophosphamide
Cytarabine
Disease Progression
Doxorubicin
Etoposide
Female
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cell Transplantation
Humans
Ifosfamide
Immunocompromised Host
Immunosuppressive Agents
Liver Transplantation
Lymphoma, T-Cell, Peripheral
Lymphoproliferative Disorders
Melphalan
Mesna
Postoperative Complications
Prednisone
Radiotherapy, Adjuvant
Transplantation, Autologous
Vidarabine
Vincristine